CRVS

14.89

1.65% -0.25

Handel nachbörslich: 14.89

Corvus Pharmaceuticals Inc (CRVS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$15.14

Offen:

$14.985

24-Stunden-Volumen:

777.88K

Relative Volume:

0.56

Marktkapitalisierung:

$1.25B

Einnahmen:

Nettoeinkommen (Verlust:

$-44.17M

KGV:

-28.31

EPS:

-0.526

Netto-Cashflow:

$-35.14M

1W Leistung:

+6.97%

1M Leistung:

-0.53%

6M Leistung:

-20.20%

1J Leistung:

+207.01%

1-Tages-Spanne:

$14.61

$15.19

1-Wochen-Bereich:

$13.43

$15.44

52-Wochen-Spanne:

$4.9165

$26.95

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Firmenname

Corvus Pharmaceuticals Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

(650) 900-4520

Adresse

901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

CRVS's Discussions on Twitter

Compare CRVS vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRVS Corvus Pharmaceuticals Inc	14.89	1.27B	0	-44.17M	-35.14M	-0.526
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-17	Eingeleitet	Goldman	Buy
2025-10-13	Eingeleitet	Barclays	Overweight
2025-01-02	Eingeleitet	H.C. Wainwright	Buy
2023-08-18	Eingeleitet	Oppenheimer	Outperform
2021-12-01	Fortgesetzt	Jefferies	Buy
2021-05-27	Eingeleitet	Cantor Fitzgerald	Overweight
2021-02-10	Herabstufung	Mizuho	Buy → Neutral
2019-09-12	Eingeleitet	Mizuho	Buy
2019-05-29	Eingeleitet	ROTH Capital	Buy
2017-08-24	Hochstufung	Credit Suisse	Underperform → Neutral
2017-05-01	Herabstufung	Credit Suisse	Neutral → Underperform
2016-04-18	Eingeleitet	Credit Suisse	Outperform
2016-04-18	Eingeleitet	Guggenheim	Buy

Alle ansehen

Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten

Aug 14, 2026

Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us

Aug 14, 2026

Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - marketbeat.com

Aug 14, 2026

Aug 13, 2026

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits

Aug 13, 2026

Aug 12, 2026

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail

Aug 12, 2026

Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha

Aug 12, 2026

HC Wainwright Issues Negative Estimate for CRVS Earnings - marketbeat.com

Aug 12, 2026

Aug 11, 2026

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Aug 11, 2026

HC Wainwright Brokers Decrease Earnings Estimates for CRVS - marketbeat.com

Aug 11, 2026

The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - marketbeat.com

Aug 11, 2026

Aug 10, 2026

H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo

Aug 10, 2026

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha

Aug 10, 2026

Aug 09, 2026

Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm

Aug 09, 2026

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com

Aug 09, 2026

Aug 08, 2026

Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail

Aug 08, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com

Aug 07, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat

Aug 07, 2026

State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan

Aug 07, 2026